menu
    • menu
    [{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NM-136","moa":"GIP","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"9 Meters Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"9 Meters Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NM-136","moa":"GIP","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"9 Meters Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"9 Meters Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kintai Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KTX-0200","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Kintai Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kintai Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kintai Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARO-ALK7","moa":"ACVR1C","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ARO-ALK7","moa":"ACVR1C","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TT-02332","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransThera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TransThera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BLX 0871","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolexis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Biolexis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"GB18","moa":"GDF-15","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kexing Biopharm \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kexing Biopharm \/ Inapplicable"}]

    Find FDA Investigational New Drug (IND) Submissions for Nutrition and Weight Loss

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kexing Biopharm

                            China arrow
                            The Battery Show Europe
                            Not Confirmed

                            Kexing Biopharm

                            China arrow
                            The Battery Show Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GB18

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kexing Biopharm's GB18 project received clearance of IND application from NMPA and FDA

                            Details : GB18 is an innovative biologic product and a nanobody targeting GDF-15 developed for the treatment of cancer cachexia.

                            Product Name : GB18

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 28, 2025

                            Lead Product(s) : GB18

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zealand Pharma

                            Denmark arrow
                            The Battery Show Europe
                            Not Confirmed

                            Zealand Pharma

                            Denmark arrow
                            The Battery Show Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Petrelintide,CT-388

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : IND Enabling

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $5,300.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Roche & Zealand Partner to Develop Petrelintide for Obesity & Overweight Therapy

                            Details : The two companies will collaborate to co-develop and co-commercialise ZP8396 (petrelintide) in combination with CT-388 for the treatment of obesity.

                            Product Name : ZP8396

                            Product Type : Peptide

                            Upfront Cash : $1,650.0 million

                            March 12, 2025

                            Lead Product(s) : Petrelintide,CT-388

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : IND Enabling

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $5,300.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Arrowhead Pharmaceuticals

                            U.S.A arrow
                            The Battery Show Europe
                            Not Confirmed

                            Arrowhead Pharmaceuticals

                            U.S.A arrow
                            The Battery Show Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARO-ALK7

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

                            Details : ARO-ALK7 is the first RNAi-based therapy to directly target a gene expressed in adipose tissue. It is being evaluated for the treatment of obesity.

                            Product Name : ARO-ALK7

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            February 25, 2025

                            Lead Product(s) : ARO-ALK7

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Arrowhead Pharmaceuticals

                            U.S.A arrow
                            The Battery Show Europe
                            Not Confirmed

                            Arrowhead Pharmaceuticals

                            U.S.A arrow
                            The Battery Show Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARO-ALK7

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Arrowhead Seeks Approval for ARO-ALK7 Phase 1/2a Trial in Obesity Treatment

                            Details : ARO-ALK7 is an ACVR1C gene expression silencer, in adipose tissue, which led to reduced body weight and fat mass with preservation of lean muscle, in obese patients

                            Product Name : ARO-ALK7

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            December 03, 2024

                            Lead Product(s) : ARO-ALK7

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Biolexis Therapeutics

                            U.S.A arrow
                            The Battery Show Europe
                            Not Confirmed

                            Biolexis Therapeutics

                            U.S.A arrow
                            The Battery Show Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BLX 0871

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biolexis Advances AMPK Agonists for Weight Loss in Preclinical Development

                            Details : BLX 0871 is an AMPK activator, which is being evaluated in the early-stage clinical trial studies for the treatment of obesity and Type 2 diabetes.

                            Product Name : BLX 0871

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 29, 2024

                            Lead Product(s) : BLX 0871

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Resalis Therapeutics

                            Italy arrow
                            The Battery Show Europe
                            Not Confirmed

                            Resalis Therapeutics

                            Italy arrow
                            The Battery Show Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RES-010

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : IND Enabling

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Resalis Therapeutics Gains Strategic Equity Investment from Sanofi

                            Details : The company intends to use the proceeds to accelerate the development of its lead investigational candidate, RES-010 for the treatment of obesity.

                            Product Name : RES-010

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            October 28, 2024

                            Lead Product(s) : RES-010

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : IND Enabling

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Arrowhead Pharmaceuticals

                            U.S.A arrow
                            The Battery Show Europe
                            Not Confirmed

                            Arrowhead Pharmaceuticals

                            U.S.A arrow
                            The Battery Show Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARO-INHBE

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Arrowhead Files for Phase 1/2a Study Clearance of ARO-INHBE for Obesity

                            Details : ARO-INHBE, a RNAi-based candidate, is designed to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E, being developed for obesity and metabolic diseases.

                            Product Name : ARO-INHBE

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            September 23, 2024

                            Lead Product(s) : ARO-INHBE

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Antag Therapeutic

                            Denmark arrow
                            The Battery Show Europe
                            Not Confirmed

                            Antag Therapeutic

                            Denmark arrow
                            The Battery Show Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT-7687

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Antag Receives FDA Clearance For IND Application For AT-7687

                            Details : AT-7687 is a peptide GIP receptor antagonist designed for once-weekly subcutaneous, currently, it is being evaluated in the treatment of obesity.

                            Product Name : AT-7687

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            September 10, 2024

                            Lead Product(s) : AT-7687

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Veru

                            U.S.A arrow
                            The Battery Show Europe
                            Not Confirmed

                            Veru

                            U.S.A arrow
                            The Battery Show Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enobosarm,Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Veru Submits IND for Enobosarm-GLP-1 to Prevent Muscle Loss

                            Details : VERU-024 (enobosarm) is a novel selective AR modulator which is beig evaluated in preclinical studies to prevent muscle loss while augmenting fat loss in combination with GLP-1 drugs for weight loss.

                            Product Name : VERU-024

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 01, 2024

                            Lead Product(s) : Enobosarm,Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Antag Therapeutic

                            Denmark arrow
                            The Battery Show Europe
                            Not Confirmed

                            Antag Therapeutic

                            Denmark arrow
                            The Battery Show Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT-7687

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : IND Enabling

                            Sponsor : Versant Ventures

                            Deal Size : $84.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Antag Therapeutics Announces €80 Million Series A Financing

                            Details : The proceeds from the financing will be used for the development of Antag's lead molecule AT-7687. It is a peptide designed to be co-administrated with current or future obesity therapies.

                            Product Name : AT-7687

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            April 12, 2024

                            Lead Product(s) : AT-7687

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : IND Enabling

                            Sponsor : Versant Ventures

                            Deal Size : $84.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth